Emtricitabine/tenofovir

Phase 3Small molecule

GSK

Emtricitabine/tenofovir is one of 30 small molecule programs targeting PrEP. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PrepCompleted

HIVActive, not recruiting

PrepPreclinical

Completed

HIVPhase 3

Active, not recruiting

Competition

Competitive Landscape

44 competitors in HIV

#DrugCompanyPhaseTrials

Tivicay

GSK

Approved

5 2

Cabenuva

GSK

Approved

2 3

Sustiva

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

6 4

Pifeltro

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—5

Epivir

GGlaxo Dba Glaxosmithkline

Phase 3

10 6

INCMGA00012

Incyte

Phase 3

1 7

Fostemsavir

GSK

Phase 3

1 8

Selzentry

GSK

Phase 2

4 9

Daraprim

FFondazione Matilde Tettamanti Menotti De Marchi Onlus

Phase 2

2 10

Fosamax

OOrganon and Co

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

ApprovedActive, not recruiting

HIV

NCT02656511

Clinical

Trials by Indication[1]

HIV2 trials

Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130)

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 3·NCT00302822·195 enrolled

Immediate Initiation of Antiretroviral Therapy During Acute HIV Infection

Active, not recruiting·UUniversity of California, San Francisco·Approved·NCT02656511·74 enrolled

Treatment1 trial

Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV

Completed· GSK logo

GSK·Phase 4·NCT00244712·688 enrolled

COVID-191 trial

Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia

Completed·UUniversidad Nacional de Colombia·Phase 2/3·NCT04359095·650 enrolled

PrEP1 trial

Feasibility of Short-Term PrEP Uptake for MSM With Episodic High-Risk for HIV

Completed·JJames Egan·N/A·NCT02495779·54 enrolled

Tenofovir1 trial

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1

Terminated· GSK logo

GSK·Phase 3·NCT01345630·813 enrolled

2 more indications

Pre-Exposure Prophylaxis (PrEP)1 trial

Evaluation of Pre-Exposure Prophylaxis (PrEP) in Pregnant and Breastfeeding Women

Completed·UUniversity of California, Los Angeles··NCT03902418·1,195 enrolled

Unspecified1 trial

Dose-Proportionality and Intra-Individual Variability of Intracellular TFV-DP and FTC-TP in Healthy Volunteers

Completed·HHIV Prevention Trials Network·Phase 1·NCT01276600·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Emtricitabine/tenofovir. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Emtricitabine/tenofovir compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Emtricitabine/tenofovir. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GSK

Emtricitabine/tenofovir

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

HIV2 trials

Treatment1 trial

COVID-191 trial

PrEP1 trial

Tenofovir1 trial

Pre-Exposure Prophylaxis (PrEP)1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News